Related Experiment Videos

miR-135a inhibits tumor metastasis and angiogenesis by targeting FAK pathway

Zhenguo Cheng1, Funan Liu2, Hongyan Zhang1

  • 1Department of Cell Biology, Key Laboratory of Cell Biology, Ministry of Public Health, and Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang 110122, China.

Oncotarget
|April 19, 2017
PubMed

Insights

MicroRNA-135a (miR-135a) is downregulated in gastric cancer, inhibiting tumor growth and metastasis. Restoring miR-135a shows therapeutic potential by targeting the focal adhesion kinase (FAK) pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Tumor metastasis is a primary driver of gastric cancer recurrence and mortality.
  • MicroRNAs (miRNAs) play crucial roles in cancer development and progression.
  • The specific role of miR-135a in gastric cancer metastasis requires further elucidation.

Purpose of the Study:

  • To investigate the expression profile of miR-135a in gastric cancer.
  • To determine the functional role of miR-135a in gastric cancer progression and metastasis.
  • To uncover the regulatory mechanisms involving miR-135a in gastric cancer.

Main Methods:

  • MicroRNA array analysis to compare miR-135a expression in metastatic vs. parental gastric cancer cell lines.
  • Analysis of miR-135a expression in human gastric cancer tissues and cell lines.
  • Functional assays (in vitro and in vivo) to assess the impact of miR-135a restoration on tumor growth, migration, invasion, and angiogenesis.
  • Bioinformatics and molecular experiments to identify downstream targets and regulatory pathways, including the focal adhesion kinase (FAK) and p53 pathways.

Main Results:

  • miR-135a expression is significantly decreased in metastatic gastric cancer cell lines and human gastric cancer tissues.
  • Lower miR-135a expression correlates with advanced TNM stage and poorer patient survival.
  • Restoration of miR-135a inhibits gastric cancer cell growth, migration, invasion, and angiogenesis by targeting the FAK pathway.
  • miR-135a is identified as a novel downstream target of the tumor suppressor p53.
  • Inhibition of FAK enhances miR-135a expression via p53 induction.

Conclusions:

  • miR-135a acts as a tumor suppressor in gastric cancer, with its downregulation promoting metastasis.
  • The miR-135a/FAK pathway represents a potential therapeutic target for gastric cancer.
  • A novel regulatory feedback loop involving p53, miR-135a, and FAK in gastric cancer is uncovered.

Related Concept Videos